PRMT5 and hepatocellular carcinoma: A recent study has shown that in the presence of high glucose, PRMT5 interacts with the cyclin dependent kinase 4 (CDK4) and promotes its release from the CDK inhibitor CDKN2A (p16INK4a), thereby facilitating G1-S transition in HCC cells [54].